Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa.
Restore Vision has raised $8.2M in total funding. The most recent round was Series B. The last funding was announced in April 2026.
Restore Vision's investors include ANRI, JIC Venture Growth Investments, SMBC Venture Capital, UntroD Capital, Kyoto University Innovation Capital.
Restore Vision is headquartered in Tokyo, Japan.
Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa.
Restore Vision is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Restore Vision — Funding & Investors." VCBacked, April 15, 2026, https://www.vcbacked.co/company/restore-vision. Accessed August 14, 2026.
VCBacked. (2026). Restore Vision — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/restore-vision
{{cite web |title=Restore Vision — Funding & Investors |url=https://www.vcbacked.co/company/restore-vision |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated